Vira M Bitko

US Patent:

20130064867, Mar 14, 2013

Filed:

Sep 10, 2012

Appl. No.:

13/608317

Inventors:

Ali I. Fattom - Ann Arbor MI, US
Tarek Hamouda - Milan MI, US
Vira Bitko - Ann Arbor MI, US

International Classification:

A61K 39/155
A61P 31/14
A61K 9/107

US Classification:

424400, 4242111, 4241921

Abstract:

The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.

US Patent:

20130011443, Jan 10, 2013

Filed:

Jul 6, 2012

Appl. No.:

13/543493

Inventors:

Ali I. Fattom - Ann Arbor MI, US
Nicolas Lukacs - Ann Arbor MI, US
Vira Bitko - Ann Arbor MI, US
Tarek Hamouda - Ann Arbor MI, US

International Classification:

A61K 9/107
A61P 37/04
A61K 39/155
B82Y 5/00

US Classification:

424400, 4242111, 977795, 977906

Abstract:

The present invention relates to RSV vaccines and methods for inducing an immune response to RSV in a subject comprising administering an RSV vaccine.

US Patent:

20200246449, Aug 6, 2020

Filed:

May 3, 2018

Appl. No.:

16/610472

Inventors:

- Ann Arbor MI, US
Vira Bitko - Ann Arbor MI, US
Shyamala GANESAN - Ann Arbor MI, US

Assignee:

NanoBio Corporation - Ann Arbor MI

International Classification:

A61K 39/12
C07K 16/06
C07K 16/10
A61P 31/14

Abstract:

The present disclosure relates to intravenous immunoglobulin (WIG) compositions specific for respiratory syncytial virus (RSV) and methods of making and using the same.

US Patent:

20200197511, Jun 25, 2020

Filed:

Nov 15, 2018

Appl. No.:

16/192478

Inventors:

- Ann Arbor MI, US
Jakub Simon - Ann Arbor MI, US
Tarek Hamouda - Milan MI, US
Vira Bitko - Ann Arbor MI, US

Assignee:

NanoBio Corporation - Ann Arbor MI

International Classification:

A61K 39/245
A61K 9/107
A61K 39/39
A61K 39/12
A61K 39/00

Abstract:

The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.

US Patent:

20200138935, May 7, 2020

Filed:

Jul 13, 2018

Appl. No.:

16/630679

Inventors:

- Ann Arbor MI, US
Vira BITKO - Ann Arbor MI, US

International Classification:

A61K 39/118
A61K 9/107
C07K 14/295
A61K 9/00

Abstract:

The present application relates to the field of human immunology, in particular, a chlamydia vaccine. The subunit vaccine composition may comprise isolated antigens from chlamydia bacteria, fusion proteins or fragments thereof, live or attenuated bacteria, or other bacterial components mixed in varied combination with a nanoemulsion, which provides a potent immune enhancer.

US Patent:

20190022210, Jan 24, 2019

Filed:

Nov 4, 2016

Appl. No.:

15/774178

Inventors:

Victor G. Solodushko - Mobile AL, US
Brian Fouty - Mobile AL, US
Vira Bitko - Mobile AL, US

International Classification:

A61K 39/155
A61P 31/14
C07K 14/005
A61K 39/12

Abstract:

The present invention relates to novel DNA vaccines, configured to induce a robust and sustained immune response, and methods of use thereof. DNA vaccines proposed herein are configured to achieve this immune response by fusing the extracellular domain of a viral fusion protein to selected antigens or antigen-binding polypeptides. After the expression and secretion of the viral fusion-antigen protein from the initially transfected cells, the natural ability of the viral fusion protein to fuse to cell membranes and actively enter cells will allow for passive delivery of the fused target epitopes into neighboring cells, thus inducing a more robust immune response. The presented method described herein allows for the use of this DNA vaccine against known antigens present in proteins produced by infectious agents or cancer cells within a subject, against unknown antigens produced by infectious agents or cancer cells within a subject, or against naturally-occurring or synthetically-derived antigens delivered by other routes, such as injection.

US Patent:

20180195086, Jul 12, 2018

Filed:

Dec 11, 2017

Appl. No.:

15/837311

Inventors:

- Mobile AL, US
Brian Fouty - Spanish Fort AL, US
Vira Bitko - Mobile AL, US

Assignee:

University of South Alabama - Mobile AL

International Classification:

C12N 15/85
C12N 9/12

Abstract:

Disclosed are genetic delivery systems that utilize genetic elements of the piggyBac family transposon system, and methods of introducing nucleic acid into target cells using the genetic delivery systems.

US Patent:

20170360919, Dec 21, 2017

Filed:

Jan 27, 2017

Appl. No.:

15/418626

Inventors:

- Ann Arbor MI, US
Tarek Hamouda - Milan MI, US
Vira Bitko - Ann Arbor MI, US

Assignee:

NanoBio Corporation - Ann Arbor MI

International Classification:

A61K 39/155
A61K 39/12
A61K 47/18
A61K 47/26
A61K 9/107
A61K 47/44
A61K 47/10
A61K 39/00

Abstract:

The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.